Stream these Chair Summit video replays for 1 year!
Incorporate evidence-based tools and strategies into routine practice to improve the differential diagnosis of migraine.
Integrate safety and efficacy data on novel strategies for migraine prevention and acute treatment into treatment decisions.
Implement essential components of shared decision-making from the National Quality Forum (NQF) Playbook to develop individualized treatment strategies to mitigate the burden of migraine.
Increase screening to identify OUD and initiate an appropriate level of intervention in vulnerable patients.
Utilize recent clinical updates on the safety and efficacy of current therapies for OUD to overcome barriers to integration in practice.
Demonstrate how collaborative care strategies can be optimized to facilitate the delivery of evidence-based treatments for OUD.
Assess treatment adherence and effective medication strategies to improve probability of remission and recovery.
Incorporate shared decision-making to facilitate using long acting injectables (LAIs) in clinical practice.
Apply DSM-5 criteria and validated rating scales in the assessment of ADHD in children, adolescents, and adults.
Apply best practices for minimizing side effects associated with traditional stimulants used to treat ADHD.
Evaluate clinical trial data for new or emerging agents with novel MOAs to treat ADHD in children, adolescents, and adults.
- Evaluate the role of pharmacgenomic testing in predicting antidepressant efficacy/response.
Examine the impact of hormone manipulation on brain function among cis-gender and trans-gender individuals.
Examine the relationship between obstetrical complications and genetic risk for neuropsychiatric illness.
Evaluate the potential effect of cannabinoids in neuropsychiatric disorders.
Formulate personalized treatment plans for patients with bipolar depression that consider mechanism of action, safety, efficacy, and dosing strategies.
Examine the epidemiology of refractory pediatric epilepsy syndromes and the role of genetic testing in early diagnosis also recognize the burden of illness of Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) on patients, caregivers, and families.
At the end of this CE activity, participants should be able to recognize the symptoms and causes of perinatal depression.and assess the role of reproductive hormones and hormone manipulation in the treatment of affective dysregulation.
This activity will help you describe the epidemiology and pathogenesis of HIV-associated neurocognitive disorders (HAND). Recognize the clinical manifestations and the use of biomarkers in the diagnosis of HAND and evaluate the recent advances in the management of HAND.
Explore early risk factors for the development of anxiety and depression.
Integrate a thorough family history in assessment of all patients at risk for Alzheimer’s disease.